SCHEMBL14720282

SCHEMBL14720282

Cc1ccccc1Cc1c(C)n[nH]c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
P2RX7 Q99572 2/20 0.45
AR P10275 1/20 0.44
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
LTA4H P09960 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
GFER P55789 1/20 0.39
CCR2 P41597 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SLC5A1 P13866 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6218818 0.84 ALDH1A1 (0.44) ALDH1A1HPGDP2RX7ARHSD17B10
SCHEMBL13516129 0.84 SMN1; SMN2 (0.50) ALDH1A1P2RX7ARSMN1; SMN2HSD17B10
SCHEMBL13666264 0.83 P2RX7 (0.57) ALDH1A1HPGDP2RX7ARSMN1; SMN2
SCHEMBL9353066 0.79 MEN1 (0.46) HPGDARLMNATSHRGFER
SCHEMBL14720127 0.78 PNMT (0.43) P2RX7SMN1; SMN2HSD17B10RECQLTAAR1
SCHEMBL14720207 0.75 PIK3CB (0.44) P2RX7AR
SCHEMBL19499628 0.74 P2RX7 (0.40) ALDH1A1HPGDP2RX7ARUSP2
SCHEMBL9572239 0.73 LMNA (0.50) ALDH1A1HPGDP2RX7ARSMN1; SMN2
SCHEMBL13516409 0.70 P2RX7 (0.45) ALDH1A1P2RX7ARSMN1; SMN2MAPT
SCHEMBL16992848 0.70 ALDH1A1 (0.47) ALDH1A1P2RX7SMN1; SMN2TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CA, PI4K2B ALDH1A1 4458/4885HPGD 4164/4885P2RX7 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.